Education
About Us
Working with TipRanks
Follow Us
Mannkind Corp. (MNKD)
NASDAQ:MNKD
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.05Last Year’s EPS
-0.01Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: -9.90%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call highlights strong growth in the endocrine business, successful partnerships, and promising developments in the pipeline, particularly with the Tyvaso DPI and Afrezza. However, there are challenges with the V-Go product and slower-than-expected growth in Afrezza's net revenue. Overall, the positive aspects outweigh the negatives, indicating a generally optimistic outlook.Company Guidance
During the MannKind Corporation's first quarter 2025 earnings call, CEO Michael Castagna and CFO Chris Prentiss provided detailed guidance on the company’s performance and strategic direction. Key highlights included a 20% growth in their endocrine business on new prescriptions (NRx) and a 14% increase on total prescriptions (TRx). The Tyvaso collaboration with United Therapeutics yielded a Q1 royalty revenue of $30 million and manufacturing revenue of $29 million. MannKind reported a non-GAAP income of $22 million, marking a 43% increase over the prior year. The company’s new and recurring prescription growth showed a 26% year-over-year increase among their top 50 prescribers. Additionally, MannKind is advancing its pipeline, with promising developments in inhaled clofazimine (MNKD-101) and nintedanib (MNKD-201), as well as plans for a pediatric expansion of Afrezza in mid-2025. The company ended the quarter with net revenues growing by 18%, supported by the strong performance of Tyvaso DPI royalties, which increased by 32% over the previous year. MannKind reported a net income of $13 million or $0.04 per share, a 24% increase from the first quarter of 2024.Endocrine Business Growth
The endocrine business grew 20% on NRxs and 14% on TRxs, indicating strong performance and demand.
Strong Partnership with United Therapeutics
The collaboration with United Therapeutics resulted in Q1 royalty revenue of $30 million and manufacturing revenue of $29 million.
Non-GAAP Income Growth
Reported non-GAAP income of $22 million, showing a 43% growth over the previous year.
Afrezza Demand and Expansion
Successful interactions and increased demand at the ATTD conference, with a focus on global expansion and pediatric opportunities.
Tyvaso DPI Revenue and Market Potential
Received $29 million in manufacturing revenue from Tyvaso DPI, with the market expected to exceed $1 billion by the end of the decade.
MNKD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MNKD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $4.85 | $4.63 | -4.54% |
Feb 26, 2025 | $5.47 | $5.23 | -4.39% |
Nov 07, 2024 | $7.39 | $7.34 | -0.68% |
Aug 07, 2024 | $5.27 | $5.01 | -4.93% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Mannkind Corp. (MNKD) report earnings?
Mannkind Corp. (MNKD) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Mannkind Corp. (MNKD) earnings time?
Mannkind Corp. (MNKD) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MNKD EPS forecast?
MNKD EPS forecast for the fiscal quarter 2025 (Q2) is 0.05.